VCA
IDXX icon

Verdence Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Verdence Capital Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,452
Closed -$816K – 679
2026
Q1 		$816K Buy
1,452
+101
+7% +$64.8K 0.05% 330
2025
Q4 		$914K Sell
1,351
-320
-19% -$218K 0.05% 296
2025
Q3 		$1.08M Buy
1,671
+168
+11% +$102K 0.06% 295
2025
Q2 		$806K Buy
+1,503
New +$719K 0.06% 296
2022
Q4 		– Sell
-1,147
Closed -$374K – 527
2022
Q3 		$374K Buy
1,147
+41
+4% +$15.1K 0.05% 326
2022
Q2 		$388K Buy
1,106
+719
+186% +$293K 0.05% 323
2022
Q1 		$212K Buy
387
+12
+3% +$6.31K 0.02% 486
2021
Q4 		$247K Buy
375
+7
+2% +$4.39K 0.03% 452
2021
Q3 		$229K Buy
+368
New +$247K 0.03% 446

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Verdence Capital Advisors's IDXX Position: Q2 2026 in Review

Verdence Capital Advisors sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 1,452 shares — an estimated $816K sold.

Verdence Capital Advisors first reported a position in IDXX in Q3 2021 and held it in 9 quarters. The position peaked at $1.08M in Q3 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Verdence Capital Advisors reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
  • Verdence Capital Advisors sold 1,452 Idexx Laboratories shares in Q2 2026, an estimated $816K.
  • Verdence Capital Advisors first reported a position in Idexx Laboratories in Q3 2021 and held it in 9 quarters.
  • Verdence Capital Advisors's Idexx Laboratories position peaked at $1.08M in Q3 2025.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Verdence Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.